Watson Receives FDA Approval Of Potassium Chloride Extended-Release Capsules

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, announced recently that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application (ANDA) for Potassium-Chloride Extended-Release Capsules USP in the 8mEq and 10mEq strengths.

Potassium-Chloride is the generic equivalent to KV Pharmaceutical's Micro-K Extencaps USP and is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. For the 12-months ending March 2008, Micro-K Extencaps and its generic equivalents had total U.S. sales of approximately $80 million, according to IMS Health. Watson plans to launch its Potassium Chloride Extended-Release product during the third quarter of 2008. The specific launch date will depend upon the timing of product validation activities and manufacturing of launch quantities.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

SOURCE: Watson Pharmaceuticals, Inc.